title: The role of phosphatidylinositol 3-kinase signaling pathways in pancreatic cancer.
abstract: BACKGROUND
  Pancreatic cancer is a highly malignant cancer and the fourth leading cause of cancer-related death. It is characterized by a rapid disease progression, a highly invasive tumor phenotype, and frequently resistance to chemotherapy. Despite significant advances in diagnosis, staging, and surgical management of the disease during the past decade, prognosis of pancreatic cancer is still dismal.
  
  
  RESULTS
  The phosphatidylinositol 3-kinase (PI3K) signaling pathways regulate cellular growth, metabolism, survival, and motility in pancreatic cancer. Pancreatic cancer is associated with a high degree of genetic alterations that can result in aberrant activation of the PI3K signaling pathway. Elucidating the role of the PI3K signaling pathway in pancreatic cancer may thus be both meaningful and necessary.
  
  
  CONCLUSIONS
  Improved knowledge of the PI3K signaling pathway in pancreatic cancer would furthermore be helpful in understanding mechanisms of tumor initiation and progression, and in identifying appropriate targeted anticancer treatment in pancreatic cancer. and IAP.
authors.affiliation: Harbin Medical University, Harbin, China.
authors.forename: Chen
authors.initials: C
authors.lastname: Sun
authors.forename: Ann H
authors.initials: AH
authors.lastname: Rosendahl
authors.forename: Roland
authors.initials: R
authors.lastname: Andersson
authors.forename: DeQuan
authors.initials: D
authors.lastname: Wu
authors.forename: Xiangdong
authors.initials: X
authors.lastname: Wang
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis; D002453:Cell Cycle / Q000502:physiology; D049109:Cell Proliferation / Q000187:drug effects; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D009361:Neoplasm Invasiveness / Q000503:physiopathology; D009389:Neovascularization, Pathologic; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D058539:Phosphatidylinositol 3-Kinase / Q000502:physiology*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011379:Prognosis; D015398:Signal Transduction / Q000502:physiology*
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D000081082:Phosphoinositide-3 Kinase Inhibitors; D058539:Phosphatidylinositol 3-Kinase